Abstract:Abstract Background B-precursor acute lymphoblastic leukemia (B-ALL) represents a heterogeneous group of hematological malignancies. Previous studies have identified distinctive gene expression profiles for several molecular subtypes of B-ALL with both biological and clinical importance. However, a proportion of B-ALL have remained poorly characterized with unclear underlying genomic abnormalities. We therefore initated a large-scale international collaborative study to comprehensively reanalyze and delineate the transcriptome landscape of 1,223 B-ALL cases using RNA-seq-driven genomic analyses. Methods RNA-seq data of 1,223 patients with B-ALL were collected from from Lund University Hospital, the Singapore and Malaysia MaSpore cohort, the Japan Adult Leukemia Study Group (JALSG), Therapeutically Applicable Research to Generate Effective Treatments (TARGET)/Children's Oncology Group(COG) cohort and Multicenter Hematology-Oncology Protocols Evaluation System (M-HOPES) by the Shanghai Institute of Hematology (SIH). We performed gene expression based analyses to identify molecular subtypes and their defining mRNA features. In parallel, we also systematically identified all gene fusions and potential driver mutations in each case. We subsequently defined B-ALL subtype by integrative genomic analysis and comprehensively evaluated their effects on outcomes across B-ALL treatment regimens. Results In this comprehensive analysis of the transcriptomic landscape of 1,223 B-ALL cases, several novel molecular subtypes of B-ALL were identified by strict statistical test capable of scrutinizing subtle genetic features. Totally, fourteen gene expression subgroups (G1-G14) were identified in the integrated B-ALL datasets. Apart from extending eight previously described subgroups (G1-G8 respectively associated to MEF2D fusions, TCF3-PBX1, ETV6-RUNX1/-like, DUX4 fusions, ZNF384 fusions, BCR-ABL1/Ph-like, high hyperdiploidy and MLL fusions), we additionally defined six transcriptome subgroups: G9 associated to both PAX5 and CRLF2 fusions; G10 and G11 respectively to hotspot mutations in PAX5 (p.P80R) and IKZF1 (p.N159Y); G12 to IGH-CEBPE fusion and hotspot mutations in ZEB2 (p.H1038R), while G13 and G14 respectively to TCF3/4-HLF and NUTM1 fusions. We also analyzed the non-silent sequence variants with available WES and RNA-seq data based on an in-house analysis criteria inspired from several published works. We next analyzed non-silent sequence variants in available WES and RNA-seq data based on an in-house analysis criteria inspired by previously published work. We identified 44 genes that were recurrently mutated in at least 1% of the cases (12/1,223 cases). Non-silent variants in NRAS, KRAS, FLT3, KMT2D, PAX5, PTPN11, CREBBP and TP53 exhibited the highest mutation frequencies (3-14%) Conclusion/Summary Leukemogenic factors contributing to B-ALL are highly heterogeneous. The large-scale cohort transcriptome sequence analysis in B-ALL revealed distinct molecular subgroups that reflect discrete paths of B-ALL, informing disease classification and prognostic stratification. Our work has thus further revealed the complexity of leukemogenesis in B-ALL and suggested the necessity of multiple therapeutic approaches. Disclosures No relevant conflicts of interest to declare.

Deciphering Subtype-Specific Expression Profiles and Involvement in TCF3::PBX1 ALL

Transcriptome-wide subtyping of pediatric and adult T cell acute lymphoblastic leukemia in an international study of 707 cases

Comprehensive analysis of differentially expressed profiles of lncRNAs and mRNAs reveals ceRNA networks in the transformation of diffuse large B-cell lymphoma.

Circular RNA differential expression in blood cell populations and exploration of circRNA deregulation in pediatric acute lymphoblastic leukemia

Transcriptome Profiling Analyses Comprehensively Identified Molecular Subgroups Of B-Precursor Acute Lymphoblastic Leukemia

Transcriptome Sequencing Allows Comprehensive Genomic Characterization of Pediatric B-Acute Lymphoblastic Leukemia in an Academic Clinical Laboratory

Single-cell RNA-seq analysis revealed the stemness of a specific cluster of B cells in acute lymphoblastic leukemia progression

Concurrent CDX2 cis-deregulation and UBTF-ATXN7L3 fusion define a novel high-risk subtype of B-cell ALL

Heterogeneity in chromatin structure drives core regulatory pathways in B-cell Acute Lymphoblastic Leukemia

Single-cell heterogeneity and dynamic evolution of Ph-like acute lymphoblastic leukemia patient with novel TPR-PDGFRB fusion gene

Profiling chromatin accessibility in pediatric acute lymphoblastic leukemia identifies subtype-specific chromatin landscapes and gene regulatory networks

Gene Expression Network and Circ_0008012 Promote Progression in MLL/AF4 Positive Acute Lymphoblastic Leukemia

Data-driven discovery of gene expression markers distinguishing pediatric acute lymphoblastic leukemia subtypes

Single-Cell Decoding of Minimal Residual Disease in Pediatric B Cell Acute Lymphoblastic Leukemia

Hsa_circ_0012152 and Hsa_circ_0001857 Accurately Discriminate Acute Lymphoblastic Leukemia From Acute Myeloid Leukemia

Transcriptional Landscape of B Cell Precursor Acute Lymphoblastic Leukemia Based on an International Study of 1,223 Cases.

The potential role of RNA sequencing in diagnosing unexplained insensitivity to conventional chemotherapy in pediatric patients with B-cell acute lymphoblastic leukemia

High-Throughput Sequencing Revealing BCR and TCR Repertoires as Potential Prognostic Biomarkers for Pediatric Patients with B-ALL

Circrnas As Prognostic Markers in Pediatric Acute Myeloid Leukemia

Profiling and Functional Analysis of Circular RNAs in Acute Promyelocytic Leukemia and Their Dynamic Regulation During All-Trans Retinoic Acid Treatment.

Sequential Approach to Improve the Molecular Classification of Childhood Acute Lymphoblastic Leukemia